Ovarian Reserve Assessment: Biomarkers and Predictive Tests

Ovarian reserve assessment uses hormonal and ultrasound markers to estimate the size of a woman's remaining pool of ovarian follicles. The most widely used measures are serum anti-Mullerian hormone (AMH), the antral follicle count (AFC) on ultrasound, and early-follicular-phase follicle-stimulating hormone (FSH). These tests are primarily quantitative indicators of how many follicles remain and how a woman may respond to ovarian stimulation, rather than direct measures of oocyte quality or of the chance of natural conception.

Definition

Ovarian reserve is the quantity (and, by extension, the reproductive potential) of the remaining primordial follicle pool; its assessment is the measurement of biomarkers — chiefly AMH, AFC, and basal FSH — that correlate with the size of that pool and with the ovarian response to gonadotropin stimulation.

Scope

This topic covers the biological basis of ovarian reserve, the principal biomarkers used to gauge it, and the appropriate interpretation and limits of those tests. It treats ovarian reserve testing as a descriptive and prognostic methodology within reproductive medicine, not as individualized clinical advice.

Core questions

• What biological quantity does each ovarian-reserve marker actually reflect?
• How well do AMH, AFC, and FSH predict response to ovarian stimulation versus the chance of conception?
• Why is ovarian reserve a marker of egg quantity rather than egg quality?
• What factors and limitations affect the interpretation of these tests?

Key concepts

• Anti-Mullerian hormone (AMH)
• Antral follicle count (AFC)
• Basal follicle-stimulating hormone (FSH)
• Diminished ovarian reserve
• Ovarian response prediction
• Quantity versus quality of oocytes
• Primordial follicle pool

Mechanisms

AMH is produced by granulosa cells of small growing (preantral and small antral) follicles, so its serum level mirrors the size of the growing-follicle pool and, indirectly, the resting reserve; it is relatively stable across the menstrual cycle (Dewailly et al., 2014). AFC counts the small antral follicles visible by transvaginal ultrasound in the early follicular phase, providing a direct sonographic estimate of the recruitable cohort. Basal FSH rises as the reserve falls because fewer follicles produce less inhibin B and estradiol, weakening negative feedback on the pituitary. Because these markers track follicle number, they predict the quantitative ovarian response to stimulation better than they predict oocyte quality or live birth.

Clinical relevance

Ovarian-reserve markers are used descriptively to characterize a woman's reproductive stage and her likely response to ovarian stimulation, and to counsel about reproductive planning; professional opinion cautions against using a single abnormal value to deny or dictate care, since these tests have limited power to predict natural fertility (Cooper et al., 2015). This entry explains the methodology and is not a basis for individual diagnostic or treatment decisions.

Epidemiology

AMH and AFC decline with age across populations and reach low levels as menopause approaches; both also vary with conditions such as polycystic ovary syndrome (higher values) and prior ovarian surgery or chemotherapy (lower values). Environmental and developmental exposures across the life course can influence the reserve a woman starts with and how quickly it depletes (Richardson et al., 2013).

Evidence & guidelines

A committee opinion of the American Society for Reproductive Medicine reviews the available tests and emphasizes interpreting them as markers of ovarian response rather than as reliable predictors of natural conception (Cooper et al., 2015). Reviews of AMH physiology describe its clinical utility and its limitations as a single biomarker (Dewailly et al., 2014).

History

Early ovarian-reserve testing relied on early-follicular FSH and the clomiphene citrate challenge test. The identification of AMH as a granulosa-cell product of small growing follicles, together with standardized antral follicle counting by transvaginal ultrasound, shifted assessment toward more stable, cycle-independent quantitative markers over the 2000s and 2010s.

Debates

Can ovarian-reserve tests predict natural fertility?

The markers reliably estimate follicle number and ovarian response to stimulation but have weak predictive value for the chance of spontaneous conception, so professional opinion warns against using them to counsel otherwise-fertile women about natural fecundity.

Seminal works

• dewailly-2014
• cooper-2015

Frequently asked questions

Does a low AMH mean a woman cannot conceive?

No. AMH reflects the number of remaining follicles and predicts how the ovaries may respond to stimulation, but it is a poor predictor of natural conception; a low value alone does not mean pregnancy is impossible.

Do ovarian-reserve tests measure egg quality?

Not directly. AMH, antral follicle count, and FSH track how many follicles remain (quantity); oocyte quality, which falls with age, is a separate dimension that these tests do not measure.